SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED

Shandong Xinhua Pharmaceutical Company Limited

719 CNE100000411

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:14 2024-06-11 EDT			5-day change	1st Jan Change
5.47 ^HKD	-1.44%		-2.32%	-5.36%

06-03	Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation	MT
05-31	Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration	CI

Shandong Xinhua Pharmaceutical Co. Ltd. Announces the Resignation of Zhang Yueshun as Supervisor

October 26, 2015 at 04:42 am

The board of directors of Shandong Xinhua Pharmaceutical Co. Ltd. announced that Mr. Zhang Yueshun, a supervisor of the company, tendered his resignation to the supervisory committee of the company for health reasons on 26 October 2015 with immediate effect.

Latest news about Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation	06-03	MT
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration	05-31	CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration	05-31	CI
Xinhua Pharmaceutical’s Sodium Bicarbonate Injection Passes Generic Drug Evaluation in China	05-29	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration	05-29	CI
Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China	05-22	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of Escitalopram Oxalate Tablets	05-22	CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation	04-11	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application	04-08	CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit	03-29	MT
Shandong Xinhua Pharmaceutical Proposes New Auditor	03-28	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China	03-13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient	02-28	CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate	01-19	CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes	12-25	CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets	12-13	MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)	12-13	CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China	12-04	MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34%	23-10-30	MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Shandong Xinhua Pharmaceutical’s AntiCoagulant Tablets Get Drug Registration Certificate	23-10-18	MT
China Grants Marketing Approval for Shandong Xinhua Pharmaceutical's Uric Acid Medication; Shares Rise 4%	23-10-11	MT
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat	23-10-10	CI

Chart Shandong Xinhua Pharmaceutical Company Limited

Duration

Period

Chart Shandong Xinhua Pharmaceutical Company Limited

More charts

Company Profile

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Companyâs main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.

Sector

Pharmaceuticals

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED	-5.36%	1.16B
ELI LILLY AND COMPANY	+48.30%	779B
NOVO NORDISK A/S	+40.67%	631B
JOHNSON & JOHNSON	-6.42%	354B
MERCK & CO., INC.	+20.70%	333B
ABBVIE INC.	+8.52%	301B
ASTRAZENECA PLC	+16.75%	249B
ROCHE HOLDING AG	-1.19%	216B
NOVARTIS AG	+10.85%	214B
AMGEN INC.	+4.63%	163B